Isabella Boyle

Isabella Boyle

Auto-generated profile, based on publicly available information

Isabella Boyle

Broad Institute of MIT and Harvard, Cambridge, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
CPClare Pacini
Clare Pacini
JDJoshua M. Dempster
Joshua M. Dempster
IBIsabella Boyle
Isabella Boyle
EGEmanuel Gonçalves
Emanuel Gonçalves
HNHanna Najgebauer
Hanna Najgebauer
Francesco IorioFrancesco Iorio
Francesco Iorio
CRISPR-Cas9 viability screens are increasingly performed at a genome-wide scale across large panels of cell lines to identify new therapeutic targets for precision cancer therapy. Integrating the datasets resulting from these studies is necessary to adequately represent the heterogeneity of human cancers and to assemble a comprehensive map of cancer genetic vulnerabilities. Here, we integrated the two largest public independent CRISPR-Cas9 screens performed to date (at the Broad and Sanger institutes) by assessing, comparing, and selecting methods for correcting biases due to heterogeneous single-guide RNA efficiency, gene-independent responses to CRISPR-Cas9 targeting originated from copy number alterations, and experimental batch effects. Our integrated datasets recapitulate findings from the individual datasets, provide greater statistical power to cancer- and subtype-specific analyses, unveil additional biomarkers of gene dependency, and improve the detection of common essential genes. We provide the largest integrated resources of CRISPR-Cas9 screens to date and the basis for harmonizing existing and future functional genetics datasets.

5 February 2025 in Nature
Verified
Journal Article
Open access
PDF file
PBPatricia C. Borck
Patricia C. Borck
IBIsabella Boyle
Isabella Boyle
KJKristina Jankovic
Kristina Jankovic
NBNolan Bick
Nolan Bick
KFKyla Foster
Kyla Foster
FVFrancisca Vazquez
Francisca Vazquez
Cancer genome alterations often lead to vulnerabilities that can be used to selectively target cancer cells. Various inhibitors of such synthetic lethal targets have been approved by the FDA or are in clinical trials, highlighting the potential of this approach1–3. Here we analysed large-scale CRISPR knockout screening data from the Cancer Dependency Map and identified a new synthetic lethal target, PELO, for two independent molecular subtypes of cancer: biallelic deletion of chromosomal region 9p21.3 or microsatellite instability-high (MSI-H). In 9p21.3-deleted cancers, PELO dependency emerges from biallelic deletion of the 9p21.3 gene FOCAD, a stabilizer of the superkiller complex (SKIc). In MSI-H cancers, PELO is required owing to MSI-H-associated mutations in TTC37 (also known as SKIC3), a critical component of the SKIc. We show that both cancer subtypes converge to destabilize the SKIc, which extracts mRNA from stalled ribosomes. In SKIc-deficient cells, PELO depletion induces the unfolded protein response, a stress response to accumulation of misfolded or unfolded nascent polypeptides. Together, our findings indicate PELO as a promising therapeutic target for a large patient population with cancers characterized as MSI-H with deleterious TTC37 mutations or with biallelic 9p21.3 deletions involving FOCAD.

7 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SMSean A. Misek
Sean A. Misek
AFAaron Fultineer
Aaron Fultineer
JKJeremie Kalfon
Jeremie Kalfon
JNJavad Noorbakhsh
Javad Noorbakhsh
IBIsabella Boyle
Isabella Boyle
JBJesse S. Boehm
Jesse S. Boehm
Reducing disparities is vital for equitable access to precision treatments in cancer. Socioenvironmental factors are a major driver of disparities, but differences in genetic variation likely also contribute. The impact of genetic ancestry on prioritization of cancer targets in drug discovery pipelines has not been systematically explored due to the absence of pre-clinical data at the appropriate scale. Here, we analyze data from 611 genome-scale CRISPR/Cas9 viability experiments in human cell line models to identify ancestry-associated genetic dependencies essential for cell survival. Surprisingly, we find that most putative associations between ancestry and dependency arise from artifacts related to germline variants. Our analysis suggests that for 1.2-2.5% of guides, germline variants in sgRNA targeting sequences reduce cutting by the CRISPR/Cas9 nuclease, disproportionately affecting cell models derived from individuals of recent African descent. We propose three approaches to mitigate this experimental bias, enabling the scientific community to address these disparities.

19 July 2024 in Genome Biology
Verified
Journal Article
Open access
PDF file
AVAlessandro Vinceti
Alessandro Vinceti
RIRaffaele M. Iannuzzi
Raffaele M. Iannuzzi
IBIsabella Boyle
Isabella Boyle
LTLucia Trastulla
Lucia Trastulla
CCCatarina D. Campbell
Catarina D. Campbell
Francesco IorioFrancesco Iorio
Francesco Iorio
Background: CRISPR-Cas9 dropout screens are formidable tools for investigating biology with unprecedented precision and scale. However, biases in data lead to potential confounding effects on interpretation and compromise overall quality. The activity of Cas9 is influenced by structural features of the target site, including copy number amplifications (CN bias). More worryingly, proximal targeted loci tend to generate similar gene-independent responses to CRISPR-Cas9 targeting (proximity bias), possibly due to Cas9-induced whole chromosome-arm truncations or other genomic structural features and different chromatin accessibility levels. Results: We benchmarked eight computational methods, rigorously evaluating their ability to reduce both CN and proximity bias in the two largest publicly available cell-line-based CRISPR-Cas9 screens to date. We also evaluated the capability of each method to preserve data quality and heterogeneity by assessing the extent to which the processed data allows accurate detection of true positive essential genes, established oncogenetic addictions, and known/novel biomarkers of cancer dependency. Our analysis sheds light on the ability of each method to correct biases under different scenarios. AC-Chronos outperforms other methods in correcting both CN and proximity biases when jointly processing multiple screens of models with available CN information, whereas CRISPRcleanR is the top performing method for individual screens or when CN information is not available. In addition, Chronos and AC-Chronos yield a final dataset better able to recapitulate known sets of essential and non-essential genes. Conclusions: Overall, our investigation provides guidance for the selection of the most appropriate bias-correction method, based on its strengths, weaknesses and experimental settings.

5 August 2026 in Nature
Verified
Journal Article
Open access
PDF file
JNJames V. Neiswender
James V. Neiswender
SMSamuel Maffa
Samuel Maffa
LBLisa Brenan
Lisa Brenan
DEDina ElHarouni
Dina ElHarouni
YYYejie Yun
Yejie Yun
FVFrancisca Vazquez
Francisca Vazquez
Despite advances in precision oncology, effective personalized treatments are still lacking for most patients with cancer1. The Cancer Dependency Map (DepMap) accelerates this field by systematically identifying cancer vulnerabilities in diverse preclinical models. Data from over 1,300 cell lines have led to the discovery of new therapeutic strategies across multiple tumour types2. However, mapping cancer vulnerabilities using traditional cell lines has limitations, including insufficient cancer subtype representation and the impact of culture conditions on perturbation responses. Here we perform 147 genome-scale CRISPR screens and multi-omic characterizations of next-generation (NextGen) cancer models (organoids and spheroids) across 10 cancer types. This strategy enables the expansion of DepMap to cover new genomic and molecular subtypes and to identify new biomarker-associated vulnerabilities. These new models also preserve transcriptional programs that are silenced in traditional cell lines and facilitate the discovery of specific gene dependencies associated with these programs. Comparisons of traditional and NextGen cancer models enable further identification of distinct effects of growth format and culture medium on gene essentiality. The integrated dataset combines data from both model types to offer a valuable, expansive resource for exploring cancer vulnerabilities and is accessible via the DepMap portal.

30 October 2025 in Genome Biology
Verified
Journal Article
Open access
PDF file
IBIsabella A. Boyle
Isabella A. Boyle
NANayeem Akram Aquib
Nayeem Akram Aquib
MKMustafa Kocak
Mustafa Kocak
RCRandy Creasi
Randy Creasi
PMPhilip Montgomery
Philip Montgomery
JDJoshua M. Dempster
Joshua M. Dempster
Overrepresentation analysis is used to identify biological enrichment in a list of genes. Here, we introduce GeneTEA, a model that ingests free-text gene descriptions and incorporates natural language processing methods to learn a sparse gene-by-term embedding, which can be treated as a de novo gene set database. In benchmarks against existing overrepresentation analysis tools, only GeneTEA properly controls false discovery while consistently surfacing the most relevant biology, doing so with less redundancy. We show that the same approach can be applied to other organisms’ genomes or compounds. Furthermore, we provide an interactive app and API for the trained GeneTEA model.